KAZIA THERAPEUTICS REPORTS PRECLINICAL DATA SHOWING PAXALISIB REPROGRAMS IMMUNOTHERAPY-RESISTANT MSS/PMMR COLORECTAL CANCER AND ENHANCES RESPONSE TO IMMUNOTHERAPY

Reuters · 1d ago

Please log in to view news